[Ergometric dose-effect study of bunitrolol (Stresson) in patients with coronary heart disease (author's transl)].
20 patients with coronary heart disease and ergometrically provocable stenocardias and electrocardiographic signs of ischemia were tested ergometrically with two different dosages (5 mg:20 mg) of the beta-blocking agent bunitrolol (Stresson) in a double-blind-test. The results obtained are in accordance with literature: The greater the ergometric stress the more effective is Stresson and vice versa. For treatment of coronary heart disease can be considered: Low dosage of Stresson in patients with stenocardias and hypoxias in high-grade exercise, high dosage of Stresson in patients with stenocardias or ischemias in low-grade exercise or rest.